NCT00034853

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 2 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

Conditions

• Arthritis, Juvenile Rheumatoid

Interventions

Type	Name	Description
DRUG	meloxicam oral suspension
DRUG	naproxen oral suspension

Timeline

• Start date: 2000-12-01
• Primary completion: 2003-06-01
• First posted: 2002-05-03
• Last updated: 2013-11-01

Locations

37 sites across 4 countries: United States, Brazil, Mexico, Ukraine